Cue Health (Nasdaq: HLTH) is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care.
Cue Health enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. Cue Health’s first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision.
Outside the United States, Cue Health has received the CE mark in the European Union, Interim Order authorization from Health Canada, and regulatory approval from India’s Central Drugs Standard Control Organisation.
Cue was founded in 2010 and is headquartered in San Diego. For more information, please visit www.cuehealth.com.
Cue Health Receives Singapore HSA Authorization for its Molecular COVID-19 Test for Self-Testing
Dec 01, 2021
- The Cue COVID-19 Test was authorized for self-testing by the Singapore Health Sciences Authority (HSA) through its Pandemic Special Access Route (PSAR) - The HSA authorization of the Cue COVID-19 Test is for home use in both symptomatic and a...
Cue determines 99.2% of the published Omicron sequences are a perfect match to the primers used in the Company's molecular COVID-19 test Cue's COVID-19 test provides highly accurate, lab-quality results, including for emerging variants, directl...
Helix and Cue Health Collaborate to Provide Individuals with Access to their COVID-19 Variant Sequencing Information
Nov 18, 2021
SAN MATEO, Calif. and SAN DIEGO, Nov. 18, 2021 /PRNewswire/ -- Helix, a leading genomics company that provides nationwide viral surveillance of respiratory disease, and Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company, announced...